Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range Paris, July 31, 2025 Q2 sales growth of 10.1% at CER1 and business EPS2 ...

French pharmaceutical company Sanofi said it is acquiring London-based Vicebio to expand its range of respiratory virus vaccines and add a non-mRNA vaccine to its pipeline.

Sanofi agreed to buy UK biotech Vicebio Ltd. for as much as $1.6 billion, gaining experimental vaccines and a technology to streamline their development.

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing a phase 1 vaccine candidate to expand its RSV pipeline beyond mRNA.

Sanofi introduced MenQuadfi, a vaccine for the prevention of meningococcal infection in children from 6 weeks of age. This complements their earlier supply of Menactra, which is intended for children ...

Sanofi acquires Blueprint Medicines Corporation for $9.1bn, gaining revenue-driving Aykavit and pipeline drug BLU-808 potential. Click for more on SNY and BPMC.

Sanofi SAN0.99%increase; green up pointing triangle agreed to buy Blueprint Medicines BPMC 0.12%increase; green up pointing triangle for up to $9.5 billion, the French drugmaker’s biggest move ...

ALAIN JOCARD/AFP via Getty Images Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases.

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.

10. FDA approves MenQuadfi meningococcal vaccine for children 6 weeks or older On May 23, 2025, the FDA expanded the approval of MenQuadfi (Sanofi) to include infants aged 6 weeks to 23 months for the ...